BACKGROUND: Somatostatin analogues are used for the treatment of pancreatic fistula, with the aim of achieving fistula closure or reduction of output. METHOD: MEDLINE, Embase and Cochrane databases were searched systematically for relevant articles followed by hand-searching of reference lists. Data on patient recruitment, intervention and outcome were extracted and meta-analysis performed where reasonable. RESULTS: Seven randomized clinical trials met the inclusion criteria and included a total of 297 patients with fistulas of the gastrointestinal tract; of these, 102 patients had fistulas of pancreatic origin. Pooling of closure rates showed no significant difference between patients treated with somatostatin analogues compared with controls: odds ratio 1·52 (95 per cent confidence interval 0·88 to 2·61). Owing to inconsistent descriptions, pooling of results was not possible for other endpoints, such as time to fistula closure. CONCLUSION: There is no solid evidence that somatostatin analogues result in a higher closure rate of pancreatic fistula compared with other treatments.
BACKGROUND: Somatostatin analogues are used for the treatment of pancreatic fistula, with the aim of achieving fistula closure or reduction of output. METHOD: MEDLINE, Embase and Cochrane databases were searched systematically for relevant articles followed by hand-searching of reference lists. Data on patient recruitment, intervention and outcome were extracted and meta-analysis performed where reasonable. RESULTS: Seven randomized clinical trials met the inclusion criteria and included a total of 297 patients with fistulas of the gastrointestinal tract; of these, 102 patients had fistulas of pancreatic origin. Pooling of closure rates showed no significant difference between patients treated with somatostatin analogues compared with controls: odds ratio 1·52 (95 per cent confidence interval 0·88 to 2·61). Owing to inconsistent descriptions, pooling of results was not possible for other endpoints, such as time to fistula closure. CONCLUSION: There is no solid evidence that somatostatin analogues result in a higher closure rate of pancreatic fistula compared with other treatments.
Authors: Christina Haane; Wolf Arif Mardin; Britta Schmitz; Sameer Dhayat; Richard Hummel; Norbert Senninger; Christina Schleicher; Soeren Torge Mees Journal: Langenbecks Arch Surg Date: 2013-10-19 Impact factor: 3.445
Authors: Riccardo Casadei; Claudio Ricci; Giovanni Taffurelli; Marielda D'Ambra; Carlo Alberto Pacilio; Carlo Ingaldi; Francesco Minni Journal: Surg Today Date: 2014-10-21 Impact factor: 2.549
Authors: Lorenzo A Orci; Graziano Oldani; Thierry Berney; Axel Andres; Gilles Mentha; Philippe Morel; Christian Toso Journal: HPB (Oxford) Date: 2013-03-06 Impact factor: 3.647